Medtronic InFuse bone graft
This article was originally published in The Gray Sheet
Executive Summary
Long-awaited PMA approval granted for treating acute, open fractures of the tibial shaft with the product, which combines recombinant human bone morphogenetic protein (rhBMP-2) and an absorbable collagen sponge. Developed and manufactured by Wyeth and marketed by Medtronic Sofamor Danek, InFuse is inserted after a fracture has been stabilized with an intermedullary nail. Previously approved for use with a spinal fusion cage for degenerative disc disease (InFuse/LT-Cage) and intended to enhance bone healing, the product was recommended for broader approval by FDA's Orthopaedic & Rehabilitation Devices Panel in 2002 (1"The Gray Sheet" Nov. 25, 2002, p. 15). Since July 2003, the device has been marketed in Europe as InductOs...
You may also be interested in...
Medtronic Launches InFuse Bone Graft To Treat Tibial Fractures
Medtronic believes its InFuse bone graft could become the standard of care, in conjunction with intramedullary nails, for acute, open tibial shaft fractures
Wyeth BMP-2 Should Be Limited To “Problem” Fractures – Panel
Wyeth's InductOs recombinant human bone morphogenic protein-2 indications for use should be limited to "problem" fractures, according to FDA's Orthopaedic and Rehabilitation Devices Panel
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”